Protein responsible for Leukemia's aggressiveness identified

April 27, 2018

(Boston)--Researchers have identified a protein critical for the aggressiveness of T-cell leukemia, a subtype of leukemia that afflicts children and adults.

The identification of ubiquitin-fusion degradation 1 (UFD1) allows for better understanding what causes leukemia to progress and become highly aggressive and treatment-resistant, and may lead to a new treatment for this type of cancer.

Leukemia is a blood cancer that affects individuals of all ages. T-cell is a particularly aggressive subtype of leukemia which is fatal in 20 percent of children and 50 percent of adults.

Researchers at Boston University School of Medicine (BUSM) conducted combined analyses of patient samples and experimental models of leukemia that resemble a major subtype of the disease. They found that UFD1 is expressed in this aggressive subtype of leukemia, and reducing its protein levels by approximately 50 percent inhibited leukemia development and progression without impacting the overall health of the experimental models.

"Because of its discouraging odds, and because current treatments remain highly toxic to patients, continued research efforts are needed to understand what causes this disease's aggressiveness and its resistance to treatment, and to identify alternative treatments that are effective but minimally toxic," explained corresponding author Hui Feng, MD, PhD, assistant professor of pharmacology and medicine at BUSM. "This research identifies the potential of targeting UFD1 to treat aggressive leukemia without causing high toxicity to normal tissues."

These findings appear in the journal Leukemia.
-end-
The research was led by Ms. Leah Huiting, a graduate student in Feng's laboratory, through collaboration of researchers at BU and the University of Massachusetts.

Funding for this study was provided by a grant from the American Cancer Society.

Boston University School of Medicine

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.